Targeting a specific protein to eliminate leukemia stem cells in chronic myeloid leukemia.
Targeting DYRK2 to eradicate leukemia stem cells in chronic myeloid leukemia.
This study is looking at a new way to help people with chronic myeloid leukemia (CML) by focusing on a protein called DYRK2, which could help make leukemia stem cells less likely to survive, so patients might be able to stop their current treatments without their cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11109689 on NIH RePORTER |
What this research studies
This research focuses on chronic myeloid leukemia (CML), a type of blood cancer that persists due to the presence of leukemia stem cells (LSCs) even after treatment with tyrosine kinase inhibitors (TKIs). The team aims to explore a new mechanism involving the protein DYRK2, which plays a crucial role in controlling the survival and self-renewal of LSCs. By investigating how to enhance DYRK2 levels, the researchers hope to develop targeted therapies that could lead to better treatment outcomes and potentially allow patients to stop TKIs without relapse. The approach includes both genetic studies and the identification of compounds that can stabilize DYRK2 in CML cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with chronic myeloid leukemia who have not achieved a complete cure with current therapies.
Not a fit: Patients with other types of leukemia or those who have not been diagnosed with chronic myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for CML, potentially allowing patients to achieve long-term remission without continuous therapy.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective, although it is still considered novel in the context of CML.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Lacorazza, Daniel — Baylor College of Medicine
- Study coordinator: Lacorazza, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.